Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

AstraZeneca shares drop after cancer drug trial setback

Thursday, October 27, 2016 12:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

AstraZeneca (NYSE:AZN) ADRs fell as much as 5.4% on Thursday after it announced that US regulators had dealt it a setback by putting a temporary halt to enrolling new patients with certain cancers in clinical trials involving its new drug durvalumab.

AstraZeneca said that the US Food and Drug Administration’s partial hold was limited to patients with head and neck cancer, following bleeding concerns.

The company said that it expects “pivotal data” on durvalumab’s effect on lung cancer in the first half of new year.

AstraZeneca shares were last seen down 3.9% at $28.43.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.